Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer

Vijay Patil; Amit Joshi; Vanita Noronha; Vivek Agarwala; Anuradha Chougule; Sadhana Kanan; Atanu Bhattacharjee; Arun Chandrasekharan; Nikhil Pande; Vijai Simha; Supriya Goud; Sucheta More; Rajiv Kumar; Abhishek Mahajan; Amit Janu; Nilendu Purandare; Kumar Prabhash

doi:10.18632/oncotarget.27214

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer

Oncotarget ◽

10.18632/oncotarget.27214 ◽

2019 ◽

Vol 10 (59) ◽

pp. 6297-6307

Author(s):

Vijay Patil ◽

Amit Joshi ◽

Vanita Noronha ◽

Vivek Agarwala ◽

Anuradha Chougule ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Egfr Mutated

Download Full-text

Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.7520 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 7520-7520 ◽

Cited By ~ 4

Author(s):

C. Zhou ◽

Y. L. Wu ◽

G. Chen ◽

J. F. Feng ◽

X. Liu ◽

...

Keyword(s):

Quality Of Life ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Activating Mutation

Download Full-text

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdt012 ◽

2013 ◽

Vol 24 (6) ◽

pp. 1615-1622 ◽

Cited By ~ 70

Author(s):

G. Chen ◽

J. Feng ◽

C. Zhou ◽

Y.-L. Wu ◽

X.-Q. Liu ◽

...

Keyword(s):

Quality Of Life ◽

Egfr Mutation ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)

Annals of Oncology ◽

10.1016/s0923-7534(20)33839-4 ◽

2012 ◽

Vol 23 ◽

pp. ix408 ◽

Cited By ~ 1

Author(s):

R. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

S. Thomas ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Download Full-text

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1052-3 ◽

2016 ◽

Vol 22 (1) ◽

pp. 79-79 ◽

Cited By ~ 1

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer ◽

10.1002/cncr.29132 ◽

2014 ◽

Vol 121 (6) ◽

pp. 883-892 ◽

Cited By ~ 30

Author(s):

Robert C. Doebele ◽

David Spigel ◽

Mustapha Tehfe ◽

Sachdev Thomas ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Chemotherapy

Download Full-text

Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.19002 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19002-19002

Author(s):

L. Crinò ◽

M. Boyer ◽

W. E. Eberhardt ◽

Z. Balikó ◽

E. F. Smit

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8025 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8025-8025 ◽

Cited By ~ 8

Author(s):

D. Lee ◽

S. Kim ◽

K. Park ◽

J. Kim ◽

J. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Download Full-text

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.187 ◽

2021 ◽

Vol 32 ◽

pp. S1456

Author(s):

B. Halmos ◽

P. Cobb ◽

M.L. Johnson ◽

L. Jain ◽

S.J. Kim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies

Annals of Oncology ◽

10.1093/annonc/mdx380.066 ◽

2017 ◽

Vol 28 ◽

pp. v488 ◽

Cited By ~ 1

Author(s):

M.C. Piccirillo ◽

A. Morabito ◽

P. Maione ◽

A. Luciani ◽

L. Cavanna ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Single Agent ◽

Small Cell ◽

Joint Analysis ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Line Chemotherapy

Download Full-text

Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps290 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS290-TPS290 ◽

Cited By ~ 1

Author(s):

R. Zinner ◽

S. Saxman ◽

G. Peng ◽

W. F. Ortuzar

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text